Latest Development Pipeline News

Tian An Australia Limited reported a statutory profit of $23.4 million for the year ended 31 December 2025, driven by strong property development sales and a gain from restructuring its major shareholder loan. The company progressed multiple residential projects and improved its net asset position amid a recovering housing market.

Noxopharm Limited's CEO and Managing Director Dr Gisela Mautner has resigned after four years with the company, including leading a key strategic pivot. The biotech firm plans to announce her successor shortly.

X2M Connect has secured a new Smart Community Agreement for 800 homes in Victoria’s Glanmire Park estate, adding an estimated $1.6 million revenue opportunity to its growing Australian smart community pipeline.

Marmota Limited is set to embark on a substantial drilling campaign targeting the southern Mainwood extension of its Greenewood gold discovery in South Australia's Gawler Craton, aiming to expand the mineralised strike to 2km.

The GPT Group delivered solid financial and operational results for 2025, growing assets under management to nearly $40 billion and advancing strategic partnerships across retail, logistics, and office sectors.

Aspen Group (ASX: APZ) has delivered robust operational and financial results for the nine months ending 31 March 2026, showing significant growth in rental income, development profits, and earnings. The company confirms it remains on track to meet its full-year guidance for FY26 and FY27 amid a supportive market environment.

NEXTDC Limited (ASX:NXT) has announced a A$1 billion wholesale offer of subordinated hybrid securities, fully backed by a binding commitment from Canadian investment group La Caisse. The capital raise aims to support NEXTDC’s growth strategy and infrastructure expansion through to FY29.

Summerset Group Holdings Limited reported a 34% increase in new occupation right sales in the first quarter of 2026 compared to the same period last year, alongside a 19% rise in resales. Despite rising fuel prices linked to geopolitical tensions, the company maintains a strong sales pipeline and cost management strategies.

Algorae Pharmaceuticals has launched a second collaboration with Peter MacCallum Cancer Centre to validate AI-predicted drug combinations across multiple cancer types, aiming to accelerate its drug development pipeline.

Infratil has upgraded its FY27 EBITDAF guidance for CDC Data Centres to A$680-720 million, citing accelerating construction and strong demand driven by AI and hyperscale cloud growth. The company also secured A$500 million equity funding and plans a bank debt upsizing to support expansion.

EVE Health Group has announced a $1.3 million capital raising through a placement of shares and free attaching options, aimed at advancing its pharmaceutical product rollout and development pipeline. Several components of the offer await shareholder approval at an upcoming general meeting.

Argenica Therapeutics has secured a nearly $4 million R&D tax incentive rebate for FY25, strengthening its cash position as it prepares for a pivotal Phase 2b trial of its neuroprotective peptide ARG-007.